摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-ethoxypropane-1,2,3-tricarboxylic acid | 178435-26-2

中文名称
——
中文别名
——
英文名称
2-ethoxypropane-1,2,3-tricarboxylic acid
英文别名
——
2-ethoxypropane-1,2,3-tricarboxylic acid化学式
CAS
178435-26-2
化学式
C8H12O7
mdl
——
分子量
220.179
InChiKey
FWHPKYSGLCDMCF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.1
  • 重原子数:
    15
  • 可旋转键数:
    7
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.62
  • 拓扑面积:
    121
  • 氢给体数:
    3
  • 氢受体数:
    7

反应信息

  • 作为产物:
    描述:
    trimethyl 2-ethoxypropane-1,2,3-tricarboxylate 、 sodium hydroxide 作用下, 以 甲醇 为溶剂, 反应 3.0h, 以77.8%的产率得到2-ethoxypropane-1,2,3-tricarboxylic acid
    参考文献:
    名称:
    Amphiphilic Long-chain Citric Acid Ethers
    摘要:
    描述了柠檬酸羟基与饱和和不饱和长链烷基基团的醚化反应。这是一种新的制备多齿酸的方法,可以作为金属或金属氧化物纳米颗粒的配体。为此,我们开发了一种合成长链ω-不饱和醇及其三氟甲烷基衍生物的方法。
    DOI:
    10.1515/znb-2009-0620
点击查看最新优质反应信息

文献信息

  • Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
    申请人:Terkeltaub Robert
    公开号:US20070021496A1
    公开(公告)日:2007-01-25
    The present invention relates to improved diagnostic methods for early detection of a risk for developing an arthritic disorder in humans, and screening assays for therapeutic agents useful in the treatment of arthritic disorders, by comparing the levels of one or more indicators of altered mitochondrial function. Indicators of altered mitochondrial function include enzymes such as mitochondrial enzymes and ATP biosynthesis factors. Other indicators of altered mitochondrial function include mitochondrial mass, mitochondrial number and mitochondrial DNA content, cellular responses to elevated intracellular calcium and to apoptogens, and free radical production. Methods of treating, and of stratifying, human patients as such methods relate to disclosed indicators of altered mitchondrial function are also provided.
    本发明涉及改进的诊断方法,用于早期检测人类发展关节炎性疾病风险,并通过比较改变的线粒体功能指标的平,筛选用于治疗关节炎性疾病的治疗剂的检测方法。改变的线粒体功能指标包括线粒体酶和ATP合成因子等酶。其他改变的线粒体功能指标包括线粒体质量、线粒体数量、线粒体DNA含量、细胞对细胞内钙离子和凋亡原的反应,以及自由基产生。还提供了与披露的改变的线粒体功能指标相关的治疗和分层人类患者的方法。
  • COMPOUNDS STABILIZING AMYLASES IN LIQUIDS
    申请人:BASF SE
    公开号:EP3677676A1
    公开(公告)日:2020-07-08
    Enzyme preparation comprising component (a): at least one compound according to general formula (I) wherein the variables of formula (i) are as follows: R1 is selected from H and C1-C10 alkylcarbonyl, wherein alkyl may be linear or branched and may bear one or more hydroxyl groups; R2, R3, R4 are independently from each other selected from H, linear C1-C8 alkyl, and branched C3-C8 alkyl, C6-C10-aryl, non-substituted or substituted with one or more carboxylate or hydroxyl groups, and C6-C10-aryl-alkyl, wherein alkyl of the latter is selected from linear C1-C8 alkyl or branched C3-C8 alkyl, wherein at least one of R2, R3, and R4 is not H component (b): at least one enzyme selected from the group of hydrolases (EC 3), preferably at least one enzyme selected from the group of amylases, more preferably at least one enzyme selected from the group of alpha-amylases (EC 3.2.1.1); and/or at least one enzyme is selected from proteases, preferably from subtilisin type proteases (EC 3.4.21.62); and optionally component (c): at least one compound selected from solvents, enzyme stabilizers different from component (a), and compounds stabilizing the liquid enzyme preparation as such.
    酶制剂,包括 组分(a):至少一种符合通式(I)的化合物 其中式(i)的变量如下: R1 选自 H 和 C1-C10 烷基羰基,其中烷基可以是直链或支链的,并可以带有一个或多个羟基; R2、R3、R4 相互独立地选自 H、直链 C1-C8 烷基和支链 C3-C8 烷基、非取代或被一个或多个羧基或羟基取代的 C6-C10 芳基和 C6-C10 芳基烷基,其中后者的烷基选自直链 C1-C8 烷基或支链 C3-C8 烷基,其中 R2、R3 和 R4 中至少有一个不是 H 组分(b):至少一种选自解酶(EC 3)的酶,最好是至少一种选自淀粉酶的酶,更优选至少一种选自α-淀粉酶EC 3.2.1.1)的酶;和/或至少一种选自蛋白酶的酶,最好是选自枯草蛋白酶EC 3.4.21.62)的酶; 以及 成分(c):至少一种化合物,选自溶剂、不同于成分(a)的酶稳定剂和稳定液态酶制剂的化合物。
  • Bioresorbable sealants for porous vascular grafts
    申请人:Lentz J. David
    公开号:US20060159720A1
    公开(公告)日:2006-07-20
    A bioresorbable sealant composition useful for impregnating implantable soft-tissue prostheses includes at least two polysaccharides in combination to form a hydrogel or sol-gel. The sealant compositions may optionally include a bioactive agent and/or be cross-linked subsequent to application of these compositions to the substrate surface.
    一种用于浸渍可植入软组织假体的生物可吸收密封剂组合物包括至少两种结合形成凝胶或溶胶凝胶的多糖。密封剂组合物可以选择性地包括生物活性剂和/或在将这些组合物应用到基底表面后进行交联。
  • [EN] IMPROVED BIORESORBABLE SEALANTS FOR POROUS VASCULAR GRAFTS<br/>[FR] MATERIAUX D'ETANCHEITE A BIORESORPTION AMELIORES POUR GREFFONS VASCULAIRES POREUX
    申请人:MEADOX MEDICALS, INC.
    公开号:WO1998010804A1
    公开(公告)日:1998-03-19
    (EN) A bioresorbable sealant composition useful for impregnating implantable soft-tissue prostheses includes at least two polysaccharides in combination to form a hydrogel or sol-gel. The sealant compositions may optionally include a bioactive agent and/or be cross-linked subsequent to application of these compositions to the substrate surface.(FR) Matériaux d'étanchéité à biorésorption utiles pour imprégner les prothèses implantables de tissus mous, comprenant au moins deux polysaccharides en combinaison pour former un hydrogel ou un sol-gel. A titre facultatif, les compositions de ces matériaux peuvent renfermer un agent bioactif et/ou être réticulées suite à l'application sur la surface de substrats.
    (EN) 一种生物可吸收密封材料复合体,可用于给可injectable的软组织假体填缝,该复合体至少包含两种多糖成分,以便形成凝胶或溶胶。该密封材料复合体可选地包含生物活性成分,可在填缝材料应用至基体表面后进行交联处理。 (FR) 一种生物可吸收的填缝材料复合体,可用于给可implantable软组织假体填缝,该复合体至少包含两种多糖成分,以便形成凝胶或溶胶。可选地,该填缝材料复合体可包含生物活性成分,并可在填缝材料应用至基体表面后进行交联处理。
  • IMPROVED BIORESORBABLE SEALANTS FOR POROUS VASCULAR GRAFTS
    申请人:Meadox Medicals, Inc.
    公开号:EP0941131B1
    公开(公告)日:2004-03-10
查看更多